Matthew Stachler, MD, PhD

Assistant Professor
+1 415 514-1902
Research Description: 

Clinically, I am a Molecular Pathologist focused on using advanced, cutting edge tests to drive personalized medicine in cancer diagnostics and treatment.

My lab works to understand the process of premalignant progression to invasive cancer, specifically focusing on cancers (esophageal and gastric adenocarcinoma) and pre-malignant conditions (columnar and intestinal metaplasia or Barrett’s esophagus) of the upper gastrointestinal tract as a model system.

As a disease that is often closely monitored and sampled, Barrett’s esophagus and esophageal adenocarcinoma provides an idea system to study the changes leading up to and driving invasive disease. Additionally, Barrett’s esophagus and esophageal adenocarcinoma are extremely important diseases to understand in their own as esophageal adenocarcinoma has one of the fastest rising incidences of any solid tumor and despite our understanding that it arises from a metaplastic field, we still do an extremely poor job of identifying patients early before advanced disease develops.

We have taken the approach to first understand the factors important in human tissues through advanced ‘omics’ and digital imaging approaches and then use this understanding to build model systems and functional studies. It is our goal to use the knowledge and understanding gained in these studies to develop novel biomarkers, screening strategies, and treatments to identify and treat people early before advanced disease develops.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Human Genetics
Research Summary: 
We strive to understand the events that drive progression of pre-malignant disease into invasive cancer, focusing on gastric and esophageal adenocarcinoma.

Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma.

Nature communications

Bao C, Tourdot RW, Brunette GJ, Stewart C, Sun L, Baba H, Watanabe M, Agoston AT, Jajoo K, Davison JM, Nason KS, Getz G, Wang KK, Imamura Y, Odze R, Bass AJ, Stachler MD, Zhang CZ

TSP-9: A Barrett's Esophagus Biomarker Better Than Pathologists?


Rubenstein JH, Stachler MD

Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights.

OncoTargets and therapy

Chatterjee A, Azevedo-Martins JM, Stachler MD